PDF fsrhguidelineprogestogenonlyinjectableapril2019pdf
Faculty of Sexual Reproductive Healthcare Clinical Guidance PDF
This guidance provides evidencebased recommendations and good practice points for health professionals on the use of progestogenonly injectables depot medroxyprogesterone acetate DMPA DepoProvera currently available in the UK
Faculty of Sexual Reproductive Healthcare Guidelines Progestogenonly Pills Clinical Effectiveness Unit March 2015 Amended April 2019 Progestogenonly Injectable Contraception Clinical Effectiveness Unit December 2014 Amended April 2019 Contraceptive Choices for Young People Clinical Effectiveness Unit March 2010 Amended May 2019
New FSRH guideline on the progestogenonly implant BMJ Sex Reprod Health 2021 Apr4727980 doi 101136bmjsrh2021201095 Authors Katherine Louise Gilmore 1 Sarah Margaret Hardman 2 3 Affiliations 1 Sexual and Reproductive Health Newcroft Centre Newcastle upon
DETAILS OF CHANGES TO ORIGINAL GUIDANCE DOCUMENT Since this set of guidelines was first published the following changes have been made March 2015 Amendments made to the document are to CPD questions 3 and 5 February 2019 Box 1 and Tables 24 updated to reflect updates to other FSRH guidance April 2019 Section 7 8 101 and 112 has been updated to reflect updates to other FSRH
PDF New FSRH guideline on the progestogenonly implant
FSRH Clinical Guideline Progestogenonly Injectables December 2014
Fsrh Clinical Guideline Progestogen Only Injectables
POI progestogenonly injectable POP progestogenonly pill RCT randomised controlled trial RCOG Royal College of Obstetricians Gynaecologists RR relative risk precautions are highlighted in the FSRH clinical guideline on Male and Female Sterilisation110 and the WHOMEC107 All methods of contraception including vasectomy if appropriate
New FSRH guideline on the progestogenonly implant PubMed
Progestogenonly implant IMP Progestogenonly injectable depot medroxyprogesterone acetate DMPA Progestogenonly pill POP FSRH guidance on the IMP1 progestogenonly injectable2 and POP3 is available on the FSRH website Progestogenonly implant IMP The recommendations in the UKMEC refer to the singlerod implant
We are the leader in the field of sexual and reproductive healthcare and the voice for professionals working in this area As a multidisciplinary professional membership organisation we set clinical guidance and standards provide training and lifelong education and champion safe and effective sexual and reproductive healthcare across the life course for all
Progestogenonly Injectables FSRH
3 What is the Mode of Action of the Progestogenonly Injectable and How Effective is it 2 4 Who is Eligible to Use the Progestogenonly Injectable 2 5 Noncontraceptive Benefits Health Concerns and Side Effects Associated with Use of the Progestogenonly Injectable 3 51 Noncontraceptive benefits 3 52 Health concerns 4 53 Side effects 8
Fsrh Clinical Guideline Progestogen Only Injectables
PDF Contraception After Pregnancy FSRH Guideline RANZCOG
FSRH Guidelines missionmrcog
PDF Progestogenonly Contraception POC compendiumappcom
fsrhguidelineprogestogenonlyinjectableapril2019 Free download as PDF File pdf Text File txt or read online for free
PDF Faculty of Sexual Reproductive Healthcare Clinical Guidance FSRH
The UK Faculty of Sexual Reproductive Healthcare FSRH has updated its 2014 guideline1 on the progestogenonly implant reexamining old evidence reflecting new evidence and highlighting changes in practice While much remains unchanged important new information and guidance is provided about the change in recommended etonogestrel implant ENGIMP insertion site duration of ENGIMP use